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UNCLASSIFIED
Project Objectives:
1. Provide scholarly and challenging Graduate Medical Education (GME) opportunities.
Objective 1 Results: GME was not conducted during this O&M FY10 project.
Note: Under AFMSA FY12 -FY13 RDT&E funded projects a formal GME training program has been established by 59 th MDW and AFRIMS investigators.
2. Complete RAPID-based test and evaluation data to support AFPMB approval of the RAPIDbased Norovirus assay for use in disease surveillance using the RAPID.
Objective 2 Results: The primary objective of this project was accomplished. Highly sensitive and specific Norovirus genotype I and II (GI and GII) TaqMan assays were developed for direct detection from stool using the "Ruggadized" Advanced Pathogen Identification Device (RAPID). The assays were optimized using Joint Biological Agent Identification and Diagnostic System (JBAIDS) reagents. Norovirus GII LoD was established at 50 virus particles per 20 µl reaction volume. Assay sensitivity was 100% and specificity was 100% in testing using a diverse panel of genotypically similar and clinically significant species and strains. The assays are applicable for use with diverse real-time PCR instrumentation to include the JBAIDS.
3. Complete JBAIDS-based test and evaluation data to support JBAIDS program manager approval of the JBAIDS-based Norovirus assay for use in environmental (non-human) surveillance using the JBAIDS.
Objective 3 Results: The results of this study support submission of a Norovirus JBAIDS Molecular Assay Transition Package to the JPO/JBAIDS program manager for qualification for use in environmental (non-human) surveillance and as a candidate assay for FDA-clearance. Under a separate protocol, the JBAIDS Molecular Assay Transition Package will be formatted as a pre-investigational device exemption (pre-IDE) document. The pre-IDE document will serve as the point of departure for discussion with the FDA Office of In Vitro Diagnostic Device Evaluation and Safety (OIVDES) to obtain guidance and clarification on specific testing requirements for the eventual clearance of the Norovirus Detection Kit.
The pre-IDE document will describe the Norovirus Detection Kit and its intended use, proposed analytical testing and clinical evaluation strategies. The intent of pre-IDE guidance meetings are to ensure that proposed testing strategy is in line with current OIVDES thinking and is sufficient to support a pre-market notification application. This will be conducted under a separate protocol.
4. Qualified by the JBAIDS program manager as a qualified candidate assay for future research targeted at getting FDA-clearance for human diagnostics on the JBAIDS under a separate research proposal.
Objective 4 Results: The investigational device exemption (IDE) will allow the Norovirus Detection Kit to be used in a clinical study in order to collect safety and effectiveness data required to support a Premarket Approval (PMA) application or a Premarket Notification [510(k)] submission to FDA. Included in FDA OIVDES guidance meetings will be discussion on potential pre-IDE submissions for high throughput systems (HTS) and microarray systems. This work will be accomplished under a separate protocol.
Summary
The fundamental objectives of this AFMSA FY10 O&M study was accomplished; real-time diarrheal disease causative agent detection capability. Highly sensitive and specific Norovirus GI and GII TaqMan assays were developed using the RAPID. The assays are applicable for use with diverse real-time PCR instrumentation to include the JBAIDS, HTS, and micro-array based systems. 
Products Completed
Norovirus GI and GII TaqMan assays were developed using real-time PCR instrumentation (RAPID). Wet assays were sensitive, specific, and provide rapid, direct detection from stool. Operational applications are FHP disease surveillance and ultimately molecular-based diagnostics. Transfer to the JBAIDS presents no technical challenges. Assay chemistry and formulation allows use on diverse real-time PCR analytic platforms. The Norovirus assays are likely candidates for transfer to microarray systems.
Purpose
Noroviruses (NoV), members of the family Caliciviridae, are the principal cause of non-bacterial acute gastroenteritis in children and adults worldwide and are presumed to be as common in military personnel as they are in the general population. Noroviruses cause about 90% of epidemic nonbacterial outbreaks of gastroenteritis around the world and may be responsible for 50% of all foodborne outbreaks of gastroenteritis in the United State (Norovirus: Technical Fact Sheet" National Center for Infectious Diseases;www.cdc.gov/ncidod/dvrd/revb/gastro/norovirusfactsheet). Noroviruses most commonly isolated in cases of acute gastroenteritis belong to genogroup I (GI) includes Norwalk virus, Desert Shield virus and Southampton virus, and II (GII), which includes Bristol virus, Lordsdale virus, Toronto virus, Mexico virus, Hawaii virus and Snow Mountain virus.
The genome of NoVs contains three open reading frames (ORFs). ORF1 encodes a large polypeptide containing amino acid sequence motifs observed in many RNA viruses, such as RNA helicase, 3C-like protease and RNA-dependent RNA polymerase (RdRp). ORF2 encodes the capsid protein with an apparent molecular mass of 58 kDa. ORF3 encodes a small protein likely involves in virion formation. Based on genome sequence analysis, NLV infecting humans can be classified into two genetic groups, genogroup I [GI] and genogroup II [GII] . These two genogroups share less than 60% sequence similarity between groups and approx. 75% similarity within each genogroup. Thus, NoVs comprises many genetically heterogeneous viruses; genogroup I consisting of 14 genotypes and genogroup II consisting of 17 genotypes. Proven real-time polymerase chain reaction (PCR) technologies are currently in use for the detection of Noroviruses. Under this study, we have enhanced the JBAIDS to perform real-time identification and diagnosis by transferring a currently existing Norovirus PCR (TaqMan) assays to the JBAIDS platform.
Problem
Non-bacterial acute gastroenteritis is considered as a military significant disease. The ability of medical personnel to accurately diagnose and recognize infectious disease threats in an operational environment is a high priority. The rapid identification of an infectious agent will allow for prompt, appropriate treatment, thereby minimizing morbidity and mortality. Additionally, knowledge about a specific infectious disease threat will allow for the implementation of prevention and control efforts to protect the fighting force.
Results

Norovirus Assays Optimization: Idaho Wet Reagent
Norovirus GI and GII assays were separately tested for components optimization using Idaho Technologies wet reagents against synthetic RNA derived from Norovirus GI and GII.
Results:
1. Optimum final concentration of MgCl 2 was 3.0 mM for both assays ( 2. Optimum final concentration of primers for GI and GII assays was summarized in Table 1 . The amplification curves are shown in Figure 3 & 4. Linearity To establish a standard curve, a synthetic RNA of Norovirus GII was used as RNA template. Eight concentrations were prepared ranging from 10 7 copies/reaction to 1 copy/reaction with triplicates for each 10 fold dilution. The standard curve was established from 5 consecutive concentrations. R 2 =-1, Slopes =3.375, Y intercept=34.11 Limit of detection LOD testing were performed with a synthetic RNA of Norovirus GII. A minimum of 58 positive results were required to establish LOD. Sixty replicates were performed at the LOD of the assay consisting of three separate runs of 20 replicates with a minimum of two instruments utilized (if available), and at least two different operators must be used. The testing will be performed on at least two different days, a minimum of two positive controls and two negative controls will be performed on each run, positive controls 10 fold higher than the concentration tested. LOD of GII assay is 50 copies/ reaction. 
Conclusion
Highly sensitive and specific Norovirus genotype I and II (GI and GII) TaqMan assays were developed for direct detection from stool using the RAPID. The assays were optimized using JBAIDS reagents. Norovirus GII LoD was established at 50 virus particles per 20 µl reaction volume. Assay sensitivity was 100% and specificity was 100% in testing using a diverse panel of genotypically similar and clinically significant species and strains. The assays are applicable for use with diverse real-time PCR instrumentation to include the JBAIDS.
